- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: VX-121 AND vertex.
Displaying page 1 of 1.
EudraCT Number: 2018-002496-18 | Sponsor Protocol Number: VX18-121-101 | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (Completed) PT (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000126-55 | Sponsor Protocol Number: VX17-121-001 | Start Date*: 2018-03-15 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000694-85 | Sponsor Protocol Number: VX20-121-103 | Start Date*: 2021-12-03 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous ... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Ongoing) DE (Ongoing) DK (Ongoing) IE (Ongoing) IT (Ongoing) GR (Ongoing) BE (Ongoing) AT (Ongoing) NL (Ongoing) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000712-31 | Sponsor Protocol Number: VX20-121-102 | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minima... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) DE (Ongoing) CZ (Ongoing) IE (Ongoing) ES (Ongoing) PT (Ongoing) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
